1. Apperley JF. Chronic myeloid leukaemia. Lancet. 2017;385(9976):1447–59.
2. Xu W, Chen B, Tong X. Chronic myeloid leukemia patient with co-occurrence of BCR – ABL junction and JAK2 V617F mutation. 2014;87–90.
3. Apperley JF. Chronic myeloid leukaemia. Lancet [Internet]. 2015;385(9976):1447–
59. Available from: http://dx.doi.org/10.1016/S0140-6736(13)62120-0
4. Liesveld J LM. Chronic Myelogenous Leukemia and Related Disorders. In: Kaushansky K, Prchal J, Press O, Lichtman M, Levi M, Burns L CM, editor. Williams Hematology 9th edition. New York: McGraw-Hill Education; 2016. p. 1437–90.
5. Arber DA, Orazi A, Hasserjian R, Borowitz MJ, Beau MM Le, Bloomfield CD, et al. The 2016 revision to the World Health Organization classi fi cation of myeloid neoplasms and acute leukemia. 2016;127(20):2391–406.
6. Vardiman JW, Melo JV, Baccarani M, Radich JP KH. Chronic myeloid leukaemia, BCR-ABL1 – positive. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA,
Stein H et al, editor. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4ta edición. Lyon: Internacional Agency for Research on Cancer; 2017. p. 29–59.
7. Hijiya N, Schultz KR, Metzler M, Millot F, Suttorp M. Perspectives Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. 2016;127(4):392–400.
8. Alikian M, Peter R, Apperley JF, Foroni L. Biomolecular Detection and Quantification Molecular techniques for the personalised management of patients with chronic myeloid leukaemia. Biomol Detect Quantif [Internet]. 2017;11:4–20. Available from: http://dx.doi.org/10.1016/j.bdq.2017.01.001
9. Ross DM, Arthur C, Burbury K, Ko BS, Mills AK, Shortt J, et al. Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors. Intern Med J [Internet]. 2018 Feb;48:5–13. Available from: http://doi.wiley.com/10.1111/imj.13716
10. Varela-Briceño C, Rodriguez-Pineda M, Jimenez-Morales F, Richmond-, Navarro J, Granado-Barrero A, et al. Situación actual de la leucemia mieloide crónica en Costa Rica. 2018;21–6.
11. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. Review Article European LeukemiaNet recommendations for the management of chronic myeloid leukemia : 2013. 2017;122(6):872–85.
12. Jc T, Wood J, Prostate FD, Castagnetti F, Gugliotta G, Baccarani M, et al. Differences among young adults , adults and elderly. 2014;
13. Lee JW, Chung NG. The treatment of pediatric chronic myelogenous leukemia in the imatinib era. 2011;54(3):111–6.
14. Gugliotta G, Castagnetti F. First-Line Treatment of Newly Diagnosed Elderly Patients with Chronic Myeloid Leukemia : Current and Emerging Strategies. 2014;627–43.
15. Seer Pediatric. Cancer Incidence and Survival among Children and Adolescents : United States SEER Program 1975-1995. 1995;
16. Krumbholz M, Karl M, Tauer JT, Thiede C, Rascher W, Suttorp M, et al. Genomic BCR – ABL1 Breakpoints in Pediatric Chronic Myeloid Leukemia.
2012;000(July):1–9.
17. Druker B, Sawyers C, Kantarjian H. ACTIVITY OF A SPECIFIC INHIBITOR OF THE BCR-ABL TYROSINE KINASE IN THE BLAST CRISIS OF CHRONIC
MYELOID LEUKEMIA AND ACUTE LYMPHOBLASTIC LEUKEMIA WITH THE PHILADELPHIA CHROMOSOME. Ne w E n g l a nd Jo u r n a l o f Me d ic i ne. 2001;344(14):1038–42.
18. Thompson PA, Kantarjian H, Cortes JE. HHS Public Access. 2017;90(10):1440–54.
